Larvin (Clopidogrel)

Clopidogrel is converted in the liver to an active metabolite that irreversibly blocks the P2Y12 ADP receptor on platelets. This inhibition prevents ADP‑mediated activation of the GPIIb/IIIa complex, reducing fibrinogen binding and platelet aggregation, thereby limiting arterial clot formation.

The appropriate dose of Larvin is determined by the prescribing clinician based on the patient’s medical condition, renal and hepatic function, and concomitant therapies. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Clopidogrel is generally not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; therefore, the drug should be used with caution and only if clearly needed, after consulting a healthcare professional.

To place an order, submit an enquiry on the Larvin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Larvin (clopidogrel) is a thienopyridine class antiplatelet that provides irreversible P2Y12 inhibition, whereas agents like aspirin act on cyclooxygenase‑1. Compared with newer agents such as ticagrelor, clopidogrel has a longer onset of action and may be affected by CYP2C19 genetic variability, but it remains widely used due to its established efficacy and safety profile.

Larvin tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Larvin is taken orally, usually with or without food, as a whole tablet. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include severe or uncontrolled bleeding, thrombotic thrombocytopenic purpura, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unusual bruising, blood in urine or stool, or signs of an allergic reaction.

Larvin should not be used by individuals with active pathological bleeding, a known hypersensitivity to clopidogrel or any component of the formulation, or severe hepatic impairment. Caution is also advised in patients with a history of hemorrhagic stroke or uncontrolled hypertension.